Association between prescription drug monitoring programs use mandates and prescription stimulants received by Medicaid enrollees.
health policy/regulation
observational data/quasi-experiments
substance use: chemical dependency
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
05
06
2023
received:
19
12
2022
accepted:
13
06
2023
medline:
13
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Prescription drug monitoring program (PDMP) use mandates are an important policy tool to curb nonmedical opioid use. However, data are scarce about their efficacy on other commonly used prescription drugs such as stimulants. We used 2010-2020 state-level secondary data from Medicaid State Drug Utilisation Data and quasi-experimental difference-in-differences research design to estimate the association between PDMP use mandates and population-adjusted stimulants (amphetamines and methylphenidate) prescribing outcomes: (i) number of prescriptions filled; and (ii) total amount reimbursed in US dollars. To account for heterogeneity in mandates across US states, two policy variables were considered: limited and expansive. Limited PDMP use mandates require prescribers or dispensers to check the PDMP only when prescribing/dispensing opioids or benzodiazepines, while expansive PDMP use mandates are non-specific to opioids/benzodiazepines and require prescribers or dispensers to check the PDMP when prescribing/dispensing targeted controlled substances in Drug Enforcement Agency Schedule II-V. The sample included 49 US states and the District of Columbia. Nevada was excluded since it implemented the PDMP mandate before the period of analysis. The state-wide implementation of the PDMP use mandate, either limited or expansive, was not associated with the number of prescriptions filled or the total amount reimbursed in US dollars for stimulants among Medicaid enrollees. There was no evidence for the associations between PDMP use mandates and stimulant prescribing among Medicaid enrollees. Future works are encouraged to replicate the study in other populations and with longer post-period analysis when the impact of the mandates might be more successfully materialised.
Substances chimiques
Analgesics, Opioid
0
Central Nervous System Stimulants
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1658-1666Subventions
Organisme : NIDA NIH HHS
ID : R01 DA042290
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA049730
Pays : United States
Informations de copyright
© 2023 Australasian Professional Society on Alcohol and other Drugs.
Références
Centers for Medicare and Medicaid Services. Medicaid Managed Care Enrollment and Program Characteristics 2019. Washington, DC: U.S. Department of Health and Human Services; 2021.
Fernandes JC, Campana D, Harwell TS, Helgerson SD. High mortality rate of unintentional poisoning due to prescription opioids in adults enrolled in Medicaid compared to those not enrolled in Medicaid in Montana. Drug Alcohol Depend. 2015;153:346-9.
Sharp MJ, Melnik TA. Poisoning deaths involving opioid analgesics-New York state, 2003-2012. MMWR Morb Mortal Wkly Rep. 2015;64:377-80.
Centers for Disease Control and Prevention. Overdose deaths involving prescription opioids among Medicaid enrollees-Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58:1171-5.
Van Draanen J, Tsang C, Mitra S, Karamouzian M, Richardson L. Socioeconomic marginalization and opioid-related overdose: a systematic review. Drug Alcohol Depend. 2020;214:108127.
Altekruse SF, Cosgrove CM, Altekruse WC, Jenkins RA, Blanco C. Socioeconomic risk factors for fatal opioid overdoses in the United States: findings from the mortality disparities in American communities study (MDAC). PLoS One. 2020;15:e0227966.
Prescription Drug Monitoring Center for Excellence. Mandating PDMP participation by medical providers: current status and experience in selected states. 2014.
Kreiner P, Nikitin R, Shields TP. Bureau of justice assistance prescription drug monitoring program performance measures report: January 2009 through June 2012. Washington, DC: US Department of Justice, Bureau of Justice Assistance; 2014.
Carey CM, Meille G, Buchmueller TC. Provider compliance with Kentucky's prescription drug monitoring Program's mandate to query patient opioid history: study examines Kentucky's prescription drug monitoring program which features a mandatory patient history query requirement for providers filling opioid prescriptions. Health Aff. 2021;40:461-8.
Meinhofer A. Prescription drug monitoring programs: the role of asymmetric information on drug availability and abuse. Am J Health Econ. 2018;4:504-26.
Meara E, Horwitz JR, Powell W, McClelland L, Zhou W, O'Malley AJ, et al. State legal restrictions and prescription-opioid use among disabled adults. N Engl J Med. 2016;375:44-53.
Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014;145:34-47.
Stein BD, Sheng F, Taylor EA, Dick AW, Sorbero M, Pacula RL. The effect of state policies on rates of high-risk prescribing of an initial opioid analgesic. Drug Alcohol Depend. 2022;231:109232.
Buchmueller TC, Carey C. The effect of prescription drug monitoring programs on opioid utilization in Medicare. Am Econ J Econ Policy. 2018;10:77-112.
Wen H, Hockenberry JM, Jeng PJ, Bao Y. Prescription drug monitoring program mandates: impact on opioid prescribing and related hospital use. Health Aff. 2019;38:1550-6.
Brown R, Riley MR, Ulrich L, Kraly EP, Jenkins P, Krupa NL, et al. Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity. Drug Alcohol Depend. 2017;178:348-54.
Sacks DW, Hollingsworth A, Nguyen T, Simon K. Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. J Health Econ. 2021;76:102397.
Pauly NJ, Slavova S, Delcher C, Freeman P, Talbert J. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings. Drug Alcohol Depend. 2018;184:26-32.
Patrick SW, Fry CE, Jones TF, Buntin MB. Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Aff. 2016;35:1324-32.
Pardo B. Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction. 2017;112:1773-83.
Graetz I, Yarbrough CR, Hu X, Howard DH. Association of mandatory-access prescription drug monitoring programs with opioid prescriptions among Medicare patients treated by a medical or hematologic oncologist. JAMA Oncol. 2020;6:1102-3.
Grecu AM, Dave DM, Saffer H. Mandatory access prescription drug monitoring programs and prescription drug abuse. J Policy Anal Manage. 2019;38:181-209.
Kim B. Must-access prescription drug monitoring programs and the opioid overdose epidemic: the unintended consequences. J Health Econ. 2021;75:102408.
Meadowcroft D, Whitacre B. Do prescription drug monitoring programs encourage prescription-or illicit-opioid abuse? Subst Abuse. 2021;42:65-75.
Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115:946-58.
Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106:686-8.
Tardelli VS, Bianco MC, Prakash R, Segura LE, Castaldelli-Maia JM, Fidalgo TM, et al. Overdose deaths involving non-BZD hypnotic/sedatives in the USA: trends analyses. Lancet Reg Health Am. 2022;10:100190.
Liang D, Guo H, Shi Y. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among US Medicaid enrollees. Subst Abuse. 2021;42:294-301.
Winstanley EL, Zhang Y, Mashni R, Schnee S, Penm J, Boone J, et al. Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug Alcohol Depend. 2018;188:169-74.
Centers for Medicare & Medicaid Services. Medicaid Facts and Figures. 2020 Available from: https://www.cms.gov/newsroom/fact-sheets/medicaid-facts-and-figures
National Institute of Drug Abuse. Commonly abused prescription drugs 2011. Available from: https://nida.nih.gov/sites/default/files/rx_drugs_placemat_508c_10052011.pdf
Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Quart J Econ. 2004;119:249-75.
McGranahan DA, Parker TS. The opioid epidemic: a geography in two phases. Washington, DC: Economic Research Service, U.S. Department of Agriculture; 2021.
Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. 2015;34:484-92.